PathAI, a company that provides AI-powered technology for advancing pathology research, announced on Tuesday that it has named Pathologist and executive leader Eric Walk, MD, FCAP, as its new chief medical officer.
In the new role, Dr Walk is to manage Clinical, Regulatory, Medical Affairs and Pathology teams.
Dr Walk has held the position of chief medical & scientific officer and SVP of Medical and Scientific Affairs at Roche Tissue Diagnostics (Ventana Medical Systems). He was a member of the Roche Medical Leadership Team establishing the global medical strategy for the Diagnostics division. He has worked at Novartis Oncology in Translational Medicine and Early Clinical Development.
Adcentrx's ADRX-0706 granted US FDA Fast Track designation to treat advanced cervical cancer
Ajinomoto and RIBOMIC announce successful extension of nucleic acid aptamer pharmacokinetics
AstraZeneca secures EU approval for Calquence combo as first-line treatment in mantle cell lymphoma
Odylia Therapeutics undertakes gene replacement therapy project for NPHP1 retinal dystrophy
Phanes Therapeutics doses first patient in peluntamig-atezolizumab combination clinical study
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg
Nutshell Therapeutics' NTS071 p53 allosteric reactivator cleared for US clinical trial
Blue Earth Therapeutics initiates Phase 2 trial in metastatic castrate resistant prostate cancer
Armata Pharmaceuticals' AP-SA02 clinical trial receives additional US DoD funding
S&E bio's SNE-101 stroke therapy approved for clinical trial
TransCode Therapeutics reports progress in metastatic cancer trial